Inquis Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Inquis Medical is a commercial-stage medical device company focused on transforming the treatment of pulmonary embolism through its intelligent AVENTUS Thrombectomy System. The system, which received FDA 510(k) clearance in June 2025, combines precision aspiration, real-time tissue sensing, and integrated blood return in a single catheter, aiming to improve procedural efficiency and patient outcomes. Backed by a $75 million Series C financing and strong clinical data from its AVENTUS IDE trial, the company is positioned to scale commercial adoption in the large and growing VTE intervention market.

Venous ThromboembolismPulmonary Embolism

Technology Platform

The AVENTUS Precision Thrombectomy System integrates intelligent tip design for targeted clot engagement, TrueClot™ real-time tissue sensing, and an integrated blood return system for autologous reinfusion in a single-catheter platform.

Opportunities

The large and growing VTE market, driven by high incidence and mortality, presents a significant opportunity.

The AVENTUS system's integrated blood reinfusion addresses a major unmet need by reducing procedural blood loss, offering a strong clinical and economic value proposition for hospital adoption.

Risk Factors

Key risks include commercial execution against established competitors, the need to demonstrate real-world clinical and economic value post-clearance, and dependence on additional funding before achieving profitability.

Protecting its core IP and expanding into new indications also pose challenges.

Competitive Landscape

Inquis Medical competes in the mechanical thrombectomy market with established players like Penumbra (Indigo and CAT systems), Boston Scientific (AngioJet, EKOS), and Inari Medical. Its key differentiators are the integrated blood reinfusion without capital equipment and real-time TrueClot™ sensing, aiming to offer a more efficient and blood-conserving single-catheter solution.

More companies in Drug Delivery & Formulation →More companies in United States →